BioWorld Science

Feb. 10, 2006

View Archived Issues

Takeda presents highlights of previous nine months

Read More

Ferritin synthesis increased by small molecule binding to mRNA

Read More

Protection for gentamicin-evoked nephrotoxicity / News in Context

Read More

Pivotal phase II/III MS trial of MBP-8298 recommended to continue

Read More

Phase I trial investigates APD-668 for type 2 diabetes

Read More

ARYx completes Series E financing

Read More

Phase I SBIR grant supports preclinical work for ALS-886 for stroke

Read More

Oscient acquires expanded rights to ramoplanin

Read More

G2 Therapies and Novo Nordisk to collaborate on antiinflammatory therapies

Read More

Xyotax receives fast track designation for PS2 women with NSCLC

Read More

ReGen Therapeutics to acquire Sciencom

Read More

Open-label phase III extension study planned for Alzhemed in North America

Read More

FDA approves IND for first phase III bladder cancer trial for Bioniche's MCC

Read More

Selective apoptotic agent isolated from an actinomycete

Read More

MF-101 studied in phase II trial for treatment of menopausal symptoms

Read More

Generic name bremelanotide approved for PT-141

Read More

Avrina shows efficacy in eczema

Read More

Alvimopan reduces time to recover GI function following bowel resection surgery

Read More

NRP-290 bioavailability studied in phase I/II trial

Read More

Factor Xa inhibitor shows promise as an antimetastatic agent

Read More

COX-2 inhibitors reduce the risk of breast cancer

Read More

Recent patents disclose novel antiinfective agents

Read More

Novel agents for endocrine-related disorders reported in recent patent literature

Read More